ELEVAR THERAPEUTICS RESUBMITS NEW DRUG APPLICATION TO FDA FOR COMBINATION OF CAMRELIZUMAB PLUS RIVOCERANIB FOR USE AS A FIRST-LINE TREATMENT OPTION FOR UNRESECTABLE OR METASTATIC HEPATOCELLULAR CARCINOMA

Reuters · 1d ago

Please log in to view news